How Does Atea Pharmaceuticals Inc (AVIR) Stock Rank on Wall Street Thursday?

Wall Street is positive on Atea Pharmaceuticals Inc (AVIR). On average, analysts give Atea Pharmaceuticals Inc a Buy rating. The average price target is $13.666, which means analysts expect the stock to climb by 73.87% over the next twelve months. That average ranking earns Atea Pharmaceuticals Inc an Analyst Rating of 16, which is better than 16% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating AVIR a Buy today. Find out what this means to you and get the rest of the rankings on AVIR!

See Full AVIR Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Atea Pharmaceuticals Inc Stock Today?

Atea Pharmaceuticals Inc (AVIR) stock is trading at $7.86 as of 1:35 PM on Thursday, Dec 2, an increase of $0.04, or 0.51% from the previous closing price of $7.82. The stock has traded between $7.69 and $7.95 so far today. Volume today is less active than usual. So far 501,242 shares have traded compared to average volume of 3,540,968 shares. Click Here to get the full Stock Report for Atea Pharmaceuticals Inc stock.